Based on the FibroGen Inc stock forecast from 0 analysts, the average analyst target price for FibroGen Inc is not available over the next 12 months. FibroGen Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of FibroGen Inc is Bearish, which is based on 2 positive signals and 9 negative signals. At the last closing, FibroGen Inc’s stock price was USD 0.71. FibroGen Inc’s stock price has changed by +27.30% over the past week, +40.06% over the past month and -61.21% over the last year.
No recent analyst target price found for FibroGen Inc
No recent average analyst rating found for FibroGen Inc
Company Overview FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Read Less
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical...Read More
Frequently Asked Questions About FibroGen Inc (FGEN) Stock
Stock Target Advisor's fundamental analysis for FibroGen Inc's stock is Bearish.
Unfortunately we do not have enough data on FGEN's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on FGEN's stock to indicate what its average analyst target is.
FGEN stock's Price/Earning ratio is 85.04.
Our analysis grades FGEN stock's Price / Earning ratio at F. This means that FGEN stock's Price/Earning ratio is above 89% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this FGEN may be a overvalued for its sector.
The last closing price of FGEN's stock was USD 0.71.
The most recent market capitalization for FGEN is USD 0.05B.
Unfortunately we do not have enough analyst data on FGEN's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains FibroGen Inc's stock.
As per our most recent records FibroGen Inc has 486 Employees.
FibroGen Inc's registered address is 409 Illinois Street, San Francisco, CA, United States, 94158.
You can get more information about it from FibroGen Inc's website at https://www.fibrogen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About FibroGen Inc (FGEN) Stock
Stock Target Advisor's fundamental analysis for FibroGen Inc's stock is Bearish.
Unfortunately we do not have enough data on FGEN's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on FGEN's stock to indicate what its average analyst target is.
FGEN stock's Price/Earning ratio is 85.04.
Our analysis grades FGEN stock's Price / Earning ratio at F. This means that FGEN stock's Price/Earning ratio is above 89% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this FGEN may be a overvalued for its sector.
The last closing price of FGEN's stock was USD 0.71.
The most recent market capitalization for FGEN is USD 0.05B.
Unfortunately we do not have enough analyst data on FGEN's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains FibroGen Inc's stock.
As per our most recent records FibroGen Inc has 486 Employees.
FibroGen Inc's registered address is 409 Illinois Street, San Francisco, CA, United States, 94158.
You can get more information about it from FibroGen Inc's website at https://www.fibrogen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FGEN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
